A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 27 Nov 2017
At a glance
- Drugs Roxadustat (Primary) ; Darbepoetin alfa
- Indications Anaemia
- Focus Registrational; Therapeutic Use
- Acronyms Dolomites
- Sponsors Astellas Pharma Europe Ltd
- 21 Nov 2017 Planned End Date changed from 1 Apr 2020 to 1 Oct 2019.
- 21 Nov 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Mar 2018.
- 21 Nov 2017 Status changed from recruiting to active, no longer recruiting.